89.00GBp+3.46%Mkt Cap: 394.10M GBpP/E: —Last update: 2026-05-13
Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. Its lead product candidate is AVA6000, a peptide drug conjugate fo…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)-15.29
PEG—
P/B—
P/S3471.53
EV/EBITDA-11.48
EV/Revenue2987.02
EPS (TTM)-0.11
EPS (Forward)-0.06
Cash Flow & Leverage
FCF Yield-4.69%
FCF Margin-16368.47%
Operating CF-23.60M GBp
CapEx (TTM)339.00K GBp
Net Debt/EBITDA-0.26
Net Debt7.76M GBp
Technical
SMA 5072.56 (+22.7%)
SMA 20064.93 (+37.1%)
Beta-0.10
S&P 52W Chg24.23%
Avg Vol (30d)2.58M
Avg Vol (10d)3.44M
Technical Indicators
RSI (14)65.6
MACD4.1275
MACD Signal2.9436
MACD Hist.+1.1839
BB Upper87.94 GBp
BB Middle77.65 GBp
BB Lower67.35 GBp
BB Width26.51%
ATR (14)5.822 GBp
Vol Ratio (20d)0.51x
52W Range
26.0095% of range92.00
52W High92.00 GBp
52W Low26.00 GBp
Profitability
Gross Margin100.00%
EBITDA Margin0.00%
Profit Margin-46761.95%
Oper. Margin-23378.57%
ROE-569.35%
ROA-109.47%
Revenue Growth0.00%
Earnings Growth—
Balance Sheet
Debt/Equity2.47
Current Ratio0.79
Quick Ratio0.65
Book Value/Sh0.0000 GBp
Cash/Share0.0330 GBp
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 GBp
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:100
Split DateJan 26, 2016
Ownership
Shares Out.453.51M
Float357.97M
Insiders1.22%
Institutions7.98%
Analyst Consensus
Rating1.7 (Buy)
Target (Mean)79.25 GBp
Target Range43.00 GBp – 103.00 GBp
# Analysts4
Company
Market Cap394.10M GBp
Enterprise Value337.53M GBp
Revenue (TTM)113.00K GBp
Gross Profit113.00K GBp
Net Income (TTM)-52.84M GBp
Revenue/Share0.0000 GBp
Fiscal Year EndDec 2024
MR QuarterJun 2025
Employees151
Last Price89.00 GBp
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN—